Status:
COMPLETED
Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function
Lead Sponsor:
Texas Tech University
Collaborating Sponsors:
Kyowa Hakko Bio Co., Ltd.
Conditions:
Menopause
Cardiovascular Risk Factor
Eligibility:
FEMALE
50-79 years
Phase:
NA
Brief Summary
Examining the effects of 4 weeks of Citrulline alone or in combination with glutathione on the arterial function of postmenopausal women.
Detailed Description
L-Citrulline is a non-protein amino acid and an efficient precursor of L-arginine, the substrate for endothelial nitric oxide synthesis. Glutathione is a tripeptide with antioxidant effects. Postmenop...
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women (defined as the absence of menstruation for at least 1 year).
- Between the ages of 50-79 years.
- Body mass index of 18.5 - 34.9 kg/m2.
- Brachial systolic blood pressure \< 150 mmHg, and diastolic blood pressure \< 90 mmHg.
- Sedentary (defined as \< 120 min/week of exercise).
- Be willing and able to comfortably abstain from any of food supplements for the period of time beginning 1 month prior to the study to the time of the termination of the study.
- Not participating as a subject in another study for at least 2 months prior to the study and for the duration of this study.
Exclusion
- Current or prior use of tobacco products, e-cigarettes or other inhaled substance.
- Use of medications and/or any supplements that may affect outcome variables (such as arginine-containing supplements, nitroglycerin, statin drugs, but not limited to those.)
- Taking hormone replacement therapy during the 3 months before the study.
- More than a moderate intake of alcohol (\>7 drink per week).
- Cardiovascular diseases, diabetes and other metabolic or chronic diseases.
- Musculoskeletal disorders that will prevent exercise performance.
- Currently taking more than one vasoactive drug for blood pressure control.
- Subject having no more than one drug for prevention, which does not affect variables, may be included, but will be diagnosed as not having a disease.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2022
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04672447
Start Date
July 1 2020
End Date
April 27 2022
Last Update
October 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TTU Kinesiology and Sport Management Building
Lubbock, Texas, United States, 79409